M6P Therapeutics
Catherine Foulon is an experienced regulatory consultant with a demonstrated history in the Pharma/Biotech industry. Since August 2020, Catherine has served as a Regulatory Consultant at M6P Therapeutics and has also held a similar role at UltraTab Laboratories since February 2018. Catherine's extensive experience includes serving as President and Lead Reg-CMC Consultant at Centaurus Consulting Group, LLC since January 2011, providing CMC regulatory consulting services while managing complex projects. Previous positions include Global Reg-CMC Consultant roles at Sarepta Therapeutics, Voyager Therapeutics, and CRISPR Therapeutics, and a CMC Project Manager role at TESARO, Inc. Catherine holds a Doctor of Philosophy (Ph.D.) degree in Nuclear Medicine from the University of Tours, France.
This person is not in any teams
M6P Therapeutics
M6P Therapeutics is developing the next-generation enzyme replacement and gene therapies for lysosomal storage disorders. We have discovered a novel method for significantly increasing mannose-6-phosphate phosphorylation of various lysosomal enzymes. This allows for markedly improved enzyme delivery to target tissues and promises improved clinical outcomes.